Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
A triplet did worse than control in first-line kidney cancer.